ArticleFrontiers in microbiology2025
Detection of EBV DNA in clinically ill patients from 2013 to 2023 in Beijing, China.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the epidemiological characteristics and infection patterns of Epstein-Barr virus (EBV) among patients at Peking Union Medical College Hospital (PUMCH) between 2013 and 2023, with a concurrent analysis of the clinical manifestations and laboratory parameters observed in patients diagnosed with EBV-associated infectious mononucleosis (IM). Methods: A retrospective analysis was conducted on data from 76,135 patients who underwent EBV DNA testing at Peking Union Medical College Hospital between 2013 and 2023. Additionally, clinical data from 152 patients diagnosed with IM from 2013 to 2024 were collected, with their clinical manifestations and laboratory parameters thoroughly evaluated. Results: The overall EBV DNA positivity rate was 6.77%, with significant variations observed across different years and age groups. The detection rate of EBV DNA in males was significantly higher than in females, with the highest detection rate observed in individuals aged over 71 years. A decline in EBV DNA detection frequency was noted during the post-COVID-19 pandemic period (2020-2023). Among EBV-related clinical entities, the highest EBV DNA positive rate (37.4%) was observed in patients with IM. In this cohort, liver function abnormalities were common: elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) by 1- to 5-fold above the upper limit of normal were present in 61 (57%) and 41 (59%) cases, respectively. Immunophenotypic analysis revealed a marked increase in the CD8 + DR+/CD8 + ratio in 67 patients (99%), accompanied by a reduction in CD19 + B-lymphocyte percentage in 62 cases (90%), indicating pronounced immune activation and B-cell suppression characteristic of acute EBV infection. Conclusion: The positive rates of EBV DNA showed sex differences and significant fluctuations between 2013 and 2023, without displaying a consistent upward trend. Persistent surveillance and heightened clinical awareness (laboratory parameters, such as ALT, AST and CD8 + DR+/CD8+) are warranted, particularly regarding IM attributable to EBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.